I-SPY2 platform-based phase II studies in breast cancer might speed up the development of new treatments. In this issue of Cancer Cell, Pusztai et al. report that adding durvalumab and olaparib to standard neoadjuvant chemotherapy significantly increases the pathological complete response rate in patients with HER2-negative breast cancer irrespective of the hormone receptor status.

中文翻译：

---

I-SPY2 平台：奥拉帕利和度伐单抗联合治疗乳腺癌的新经验

基于 I-SPY2 平台的乳腺癌 II 期研究可能会加速新疗法的开发。在本期《癌细胞》中，Pusztai 等人。报告称，在标准新辅助化疗中加入 durvalumab 和 olaparib 可显着提高 HER2 阴性乳腺癌患者的病理完全缓解率，而与激素受体状态无关。